BCM
CARM

Bayesian Capital Management’s Carisma Therapeutics CARM Stock Holding History

Bayesian Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-625
Closed -$19K – 528
2019
Q2 		$19K Sell
625
-509
-45% -$15.2K ﹤0.01% 482
2019
Q1 		$23K Buy
1,134
+434
+62% +$7.49K ﹤0.01% 522
2018
Q4 		$20K Buy
+700
New +$22.3K ﹤0.01% 588

Other funds holding CARM

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bayesian Capital Management's CARM Position: Q3 2019 in Review

Bayesian Capital Management sold out of Carisma Therapeutics (CARM) in Q3 2019, closing a stake of 625 shares — an estimated $19K sold.

Bayesian Capital Management first reported a position in CARM in Q4 2018 and held it in 3 quarters. The position peaked at $23K in Q1 2019. 37 funds tracked by Wall St. Rank hold CARM as of Q3 2019.

  • Bayesian Capital Management reported no remaining Carisma Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Bayesian Capital Management sold 625 Carisma Therapeutics shares in Q3 2019, an estimated $19K.
  • Bayesian Capital Management first reported a position in Carisma Therapeutics in Q4 2018 and held it in 3 quarters.
  • Bayesian Capital Management's Carisma Therapeutics position peaked at $23K in Q1 2019.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2019.

Based on Bayesian Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.